Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1

Conditions

Stomach Neoplasms 1Rectal Neoplasms 1Pancreatic Neoplasms 1Gastrointestinal Stromal Tumors 1Esophageal Neoplasms 1Colorectal Neoplasms 1

Interventions

Oxaliplatin 3Cisplatin 3pembrolizumab 2Leucovorin 2Irinotecan 2Gemcitabine 2Fluorouracil 2Erlotinib Hydrochloride 2Carboplatin 2umbralisib 1sodium thiosulfate 1motexafin lutetium 1montanide ISA 51 1entinostat 1ciforadenant 1cediranib 1X-Rays 1Thalidomide 1Standard of Care 1Specimen Handling 1Serotonin Plasma Membrane Transport Proteins 1Ritonavir 1Radiotherapy 1Radiosurgery 1Radionuclide Imaging 1Quality of Life 1Psychology, Positive 1Psychiatric Rehabilitation 1Practice Guidelines as Topic 1Platinum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Rectal Neoplasms × umbralisib × Sarcoma × Clear all
NCT02574663 2019-10-02

TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors

TG Therapeutics, Inc.

Phase 1 Completed
66 enrolled
GastrointestinalSarcoma

Esophageal Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡